Researchers from Georgetown University Medical Center have announced plans to perform a multi-site study to investigate the healing effects of huperzia, a type of moss commonly used in traditional Chinese medicine. The purpose of the study, which will be conducted at 23 locations in 12 states and the District of Columbia, is to determine the effectiveness of an ingredient found in huperzia in improving cognitive function in patients with Alzheimer's disease.
At the center of the study is huperzine A, a chemical derived from huperzia that prevents the breakdown of acetylcholine, a neurotransmitter. Because loss of acetylcholine function is a characteristic of several disorders of brain function, many scientists believe that huperzine A can be effective in stopping the spread of Alzheimer's disease. Other evidence has suggested huperzine A may protect brain tissue and improve memory in patients with age-related dementia.
In traditional Chinese medicine, huperzia has been used to treat not only Alzheimer's disease, but also conditions such as fever, blood loss and irregular menstruation. While dozens of Chinese studies have suggested huperzine A is both safe and effective, only a handful of controlled clinical trials assessing the herb's efficacy or toxicity have been published outside of China.
"This trial is essential to better understand the promise of huperzine A," said Dr. Paul Aisen, a professor of neurology at Georgetown and the trial's project director. "Based on studies in China, huperzine A may be more effective and better tolerated than currently prescribed drugs for Alzheimer's disease. In addition, laboratory studies suggest that huperzine may have unique effects that could slow down the progression of the disease."
The huperzine trial will enroll approximately 150 individuals age 55 or older, all diagnosed with mild to moderate Alzheimer's disease, and for whom currently approved treatments for Alzheimer's have proved ineffective or intolerable. Upon enrollment, patients will be randomly assigned to one of three groups. The first group will receive a supplement containing 200 micrograms of huperzine twice per day; the second will receive a supplement containing 400 micrograms of huperzine twice per day; and the third group will receive a placebo.
The first portion of the trial will last 16 weeks. To measure the effectiveness of huperzine in treating Alzheimer's disease, subjects will take a battery of tests that assess memory, behavior, and other aspects of cognitive function at the end of the 16-week trial period, with results of the placebo group measured against each of the huperzine groups. Thereafter, patients in all three groups will have the opportunity to receive active huperzine supplements for up to an additional 24 weeks, with another set of cognitive tests conducted at the end of the 24-week period.
The trial is funded in part through a grant from the National Institutes of Health. Based on its results, the scientists will then determine whether to seek funding for a larger, definitive study.
A complete listing of sites participating in the huperzine trial appears below. Additional details can be found at the Georgetown Memory Disorders Program's Web site (http://memory.georgetown.edu). Practitioners interested in having their patients participate in the trial are encouraged to contact the program by phone at (202) 784-6674, or by e-mail at memory@georgetown.edu.
| Sites Participating in the Georgetown Huperzine A Trial | |||
| Site Contact Person | City/States Contact Information | ||
| University of Alabama-Birmingham Jo Ann Parrish | Birmingham, Ala. (205) 934-6223 jparrish@uab.edu | ||
| University of California, Davis Barbara Livingston-Henk | Sacramento, Calif. (916) 734-6750 barbara.henk@ucdmc.ucdavis.edu | ||
| University of California, Irvine Catherine McAdams-Ortiz | Irvine, Calif. (949) 824-8726 cmcadams@uci.edu | ||
| University of California, San Diego Karen Wetzel | La Jolla, Calif. (858) 622-5822 kwetzel@ucsd.edu | ||
| University of California, San Francisco Carrie Meer | San Francisco (415) 476-6880 cmeer@memory.ucsf.edu | ||
| University of Southern California Randall Sanabria | Los Angeles (323) 442-7600 randalls@usc.edu | ||
| Georgetown University Medical Center Carolyn Ward | Washington, D.C. (202) 784-6671 cw2@georgetown.edu | ||
| Howard University School of Medicine Kamilah Owens Adediran | Washington, D.C. (202) 865-7895 kamilahadediran@yahoo.com | ||
| Baumel-Eisner Ft. Lauderdale Rachel Rodriguez | Ft. Lauderdale, Fla. (954) 720-1899 rachel.rodriguez@caremark.com | ||
| Premiere Research Institute Cora Kessel | West Palm Beach, Fla. (561) 845-0500, ext. 136 eneuro@aol.com | ||
| University of South Florida, Tampa Amanda Smith | Tampa, Fla. (813) 974-4355 asmith2@hsc.usf.edu | ||
| Emory University Ann Snider | Atlanta, Ga. (404) 728-6541 asnider@emory.edu | ||
| Rush University Medical Center Julie Bach | Chicago, Ill. (312) 942-8264 julie.bach@rush.edu | ||
| University of North Carolina Wendy Robertson | Chapel Hill, N.C. (919) 966-6727 robertsw@neurology.unc.edu | ||
| University of Medicine and Dentistry of New Jersey Julie Coleman | Piscataway, N.J. (732) 235-4907 colemajs@cmhc.umdnj.edu | ||
| University of Nevada School of Medicine Gail Vranesh | Las Vegas (702) 671-5079 gvranseh@med.unr.edu | ||
| Mt. Sinai School of Medicine Edwin Canas | New York City (212) 241-1514 edwin.canas@mssm.edu | ||
| New York University Medical Center Suzanne DAgostino | New York City (212) 263-5708 suzanne.blaisdell@med.nyu.edu | ||
| University of Rochester Medical Center Colleen McCallum | Rochester, N.Y. (585) 760-6547 colleenmccallum@urmc.rochester.edu | ||
| Oregon Health and Science University Dana Waichunas | Portland, Ore. (503) 494-9399 waichuna@ohsu.edu | ||
| University of Pittsburgh Thomas Baumgartner | Pittsburgh (412) 692-2716 baumgartnertc@msx.upmc.edu | ||
| Medical University of South Carolina Don Bagwell | North Charleston, S.C. (843) 740-1592, ext. 29 bagwelld@musc.edu | ||
| University of Texas-Southwestern Medical Center Kathleen Koch | Dallas, Texas (214) 648-7462 kathleen.koch@utsouthwestern.edu | ||
References
Structured water (H3O2) can be considered a fourth state of water between liquid and solid. It has the hexagonal structure of ice; however, missing a critical bond, it behaves more like a gel than a solid, but retains some of its crystalline structure.
In the past five years of my clinical practice, I have seen an astonishing upsurge in the chronic use of proton-pump inhibitor (PPI) medications for the gastrointestinal issue diagnosed by allopathic medicine as GERD. It is not uncommon to encounter patients taking these prescriptions for five-plus years.
Working with chronically ill patients entails acknowledging the reality that not all patients will survive their diagnosis. Chinese medicine and acupuncture play a crucial role in palliative and end-of-life care, addressing medication and disease side effects, alleviating pain associated with death, reducing anxiety and stress, and helping patients find peace during the dying process.
